SCHEMBL2249992

SCHEMBL2249992

CC(C)(Cc1ccc(F)cc1)N[C@@H](CCC(N)=O)C(=O)OC(=O)c1ccc(-c2ccc3c(c2)CCO3)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 1/20 0.40
MMP8 P22894 1/20 0.40
MMP12 P39900 1/20 0.40
ADAMTS5 Q9UNA0 1/20 0.40
CHRM5 P08912 3/20 0.39
CHRM1 P11229 3/20 0.39
TRPM8 Q7Z2W7 1/20 0.38
TAS1R3 Q7RTX0 3/20 0.37
TAS1R1 Q7RTX1 3/20 0.37
FFAR1 O14842 1/20 0.37
RAB9A P51151 3/20 0.36
NPC1 O15118 2/20 0.36
MAPT P10636 1/20 0.36
FFAR4 Q5NUL3 1/20 0.36
GSK3B P49841 1/20 0.35
ABCB1 P08183 1/20 0.35
ABCG2 Q9UNQ0 1/20 0.35
CLK1 P49759 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
CHRM2 P08172 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2247856 0.94 MMP2 (0.40) MMP2MMP8MMP12ADAMTS5CHRM5
SCHEMBL2250802 0.89 MMP2 (0.41) MMP2MMP8MMP12ADAMTS5TAS1R3
SCHEMBL2249892 0.88 MMP2 (0.49) MMP2MMP8MMP12ADAMTS5RAB9A
SCHEMBL2246684 0.86 MMP2 (0.36) MMP2MMP8MMP12ADAMTS5CHRM5
SCHEMBL2248771 0.85 MMP2 (0.44) MMP2MMP8MMP12ADAMTS5RAB9A
SCHEMBL2254236 0.85 MMP2 (0.47) MMP2MMP8MMP12ADAMTS5FFAR1
SCHEMBL2247595 0.84 MMP2 (0.43) MMP2MMP8MMP12ADAMTS5
SCHEMBL2242489 0.83 MMP2 (0.46) MMP2MMP8MMP12ADAMTS5MAPT
SCHEMBL2247684 0.83 MMP2 (0.45) MMP2MMP8MMP12ADAMTS5
SCHEMBL2248057 0.83 MMP2 (0.43) MMP2MMP8MMP12ADAMTS5MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1902014-A2 GLUTAMATE AGGRECANASE INHIBITORS Wyeth (US) 2008-03-26 EP claimed
US-20070043066-A1 Glutamate aggrecanase inhibitors WYETH (US) 2007-02-22 US claimed
WO-2007008994-A2 GLUTAMATE AGGRECANASE INHIBITORS WYETH (US) 2007-01-18 WO claimed
US-7998965-B2 Glutamate aggrecanase inhibitors WYETH LLC (US) 2011-08-16 US disclosed
US-20100010012-A1 GLUTAMATE AGGRECANASE INHIBITORS WYETH (US) 2010-01-14 US disclosed
US-7553873-B2 Glutamate aggrecanase inhibitors WYETH (US) 2009-06-30 US disclosed
US-20070043066-A1 Glutamate aggrecanase inhibitors WYETH (US) 2007-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100010012-A1 GLUTAMATE AGGRECANASE INHIBITORS ADAMTS5, ADAMTS1, ADAMTS7 MMP2 49/4885MMP8 70/4885MMP12 54/4885
US-20070043066-A1 Glutamate aggrecanase inhibitors ADAMTS5, ADAMTS1, ADAMTS7 MMP2 49/4885MMP8 70/4885MMP12 54/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.